Cytori gains European OK for stem cell tech

Shares of Cytori Therapeutics (CYTX) were buoyed by the news that European regulators have approved its stem cell technology for a range of procedures including breast reconstruction surgery and tissue repair.

Cytori's Celution system is designed to extract stem cells from a person's fat tissue so they can be used to create a graft that can be used in the repair work. Just last spring Cytori touted mid-stage data for its adult stem cell therapy for heart damage.

"The expanded indications improve our ability to provide the Celution System to European hospitals in addition to the private-pay plastic and cosmetic surgery clinics," said Marc Hedrick, president of Cytori. "These claims, coupled with our expanded focus on reimbursement, will make this technology more broadly available, not just for a wider range of procedures but to a greater population of patients."

- here's the Cytori release
- and here's the Reuters report

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.